Genotype-phenotype correlation in cystic fibrosis: the role of modifier genes.

More than 1,000 mutations have been identified in the cystic fibrosis (CF) transmembrane regulator (CFTR) disease gene. The impact of these mutations on the protein and the wide spectrum of CF phenotypes prompted a series of Genotype-Phenotype correlation studies. The CFTR genotype is invariably correlated with pancreatic status-in about 85% of cases with pancreatic insufficiency and in about 15% of cases with pancreatic sufficiency. The correlations between the CFTR genotype and pulmonary, liver, and gastrointestinal expression are debatable. The heterogeneous phenotype in CF patients bearing the same genotype or homozygotes for nonsense mutations implicated environmental and/or genetic factors in the disease. However, the discordant phenotype observed in CF siblings argued against a major role of environmental factors and suggested that genes other than CFTR modulate the CF phenotype. A locus that modulates gastrointestinal expression was identified in mice and subsequently in humans. By analyzing nine CF patients discordant for meconium ileus we were able to show that this locus had a dominant effect. Moreover, in a collaborative study we found a higher rate of polymorphisms in beta-defensin genes 1 and 2 in CF patients and in controls. In another multicenter study mutations in alpha-1 antitrypsin (A1AT) and mannose binding lectin genes were found to be independent risk factors for liver disease in CF patients. The body of evidence available suggests that the variegated CF phenotype results from complex interactions between numerous gene products.

[1]  B. Kerem,et al.  Genotype‐phenotype correlations in cystic fibrosis , 1996, Pediatric pulmonology.

[2]  M. Corey,et al.  Familial concordance of pancreatic function in cystic fibrosis. , 1989, The Journal of pediatrics.

[3]  D Markiewicz,et al.  The relation between genotype and phenotype in cystic fibrosis--analysis of the most common mutation (delta F508). , 1990, The New England journal of medicine.

[4]  K. Morgan,et al.  An alpha1-antitrypsin enhancer polymorphism is a genetic modifier of pulmonary outcome in cystic fibrosis , 2001, European Journal of Human Genetics.

[5]  D. Bozon,et al.  Mutation analysis in 600 French cystic fibrosis patients. , 1994, Journal of medical genetics.

[6]  B. Kerem,et al.  Correlation between genotype and phenotype in patients with cystic fibrosis. , 1994, The New England journal of medicine.

[7]  N. Høiby,et al.  IgG subclass antibody responses to alginate from Pseudomonas aeruginosa in patients with cystic fibrosis and chronic P. aeruginosa infection , 1992, Pediatric pulmonology.

[8]  M. Tanner,et al.  Prevalence of liver disease in cystic fibrosis. , 1991, Archives of disease in childhood.

[9]  V. Raia,et al.  Severe liver impairment in a cystic fibrosis-affected child homozygous for the G542X mutation. , 1997, American journal of medical genetics.

[10]  L. Tsui,et al.  Lung disease in mice with cystic fibrosis. , 1997, The Journal of clinical investigation.

[11]  L. Tsui,et al.  Modulation of disease severity in cystic fibrosis transmembrane conductance regulator deficient mice by a secondary genetic factor , 1996, Nature Genetics.

[12]  Charles R.scriver,et al.  The Metabolic basis of inherited disease , 1989 .

[13]  L. Tsui,et al.  Higher proportion of intact exon 9 CFTR mRNA in nasal epithelium compared with vas deferens. , 1997, Human molecular genetics.

[14]  N. Shaheen,et al.  Is the hemochromatosis gene a modifier locus for cystic fibrosis? , 1998, Genetic testing.

[15]  M. Schwartz,et al.  Severity of cystic fibrosis in patients homozygous and heterozygous for ΔF508 mutation , 1991, The Lancet.

[16]  J H VAN DE KAMER,et al.  Rapid method for the determination of fat in feces. , 1949, The Journal of biological chemistry.

[17]  M. Corey,et al.  DNA marker haplotype association with pancreatic sufficiency in cystic fibrosis. , 1989, American journal of human genetics.

[18]  M. Corey,et al.  Clinical and genetic comparisons of patients with cystic fibrosis, with or without meconium ileus. , 1989, The Journal of pediatrics.

[19]  Dagmar Ringe,et al.  A transport problem? , 1990, Nature.

[20]  M. Corey,et al.  Cystic fibrosis patients bearing both the common missense mutation Gly----Asp at codon 551 and the delta F508 mutation are clinically indistinguishable from delta F508 homozygotes, except for decreased risk of meconium ileus. , 1992, American journal of human genetics.

[21]  L. Tsui,et al.  Erratum: Identification of the Cystic Fibrosis Gene: Cloning and Characterization of Complementary DNA , 1989, Science.

[22]  D. Lomas,et al.  Alpha-1 antitrypsin deficiency alleles and severe cystic fibrosis lung disease , 1998, Thorax.

[23]  L. Tsui,et al.  In vivo measurements of ion transport in long-living CF mice. , 1996, Biochemical and biophysical research communications.

[24]  D. Lomas,et al.  Alpha1-antitrypsin deficiency alleles and the Taq-I G-->A allele in cystic fibrosis lung disease. , 1998, The European respiratory journal.

[25]  V. Bafna,et al.  Human beta-defensin 2 is a salt-sensitive peptide antibiotic expressed in human lung. , 1998, The Journal of clinical investigation.

[26]  M. Knowles,et al.  Rapid characterization of the variable length polythymidine tract in the cystic fibrosis (CFTR) gene: Association of the 5T allele with selected CFTR mutations and its incidence in atypical sinopulmonary disease , 1997, Human mutation.

[27]  G. Döring.  Serine proteinase inhibitor therapy in α1‐antitrypsin inhibitor deficiency and cystic fibrosis , 1999 .

[28]  A. Prince,et al.  Pseudomonas aeruginosa pili bind to asialoGM1 which is increased on the surface of cystic fibrosis epithelial cells. , 1993, The Journal of clinical investigation.

[29]  M. Welsh,et al.  Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis , 1993, Cell.

[30]  D. Porteous,et al.  Lung disease in the cystic fibrosis mouse exposed to bacterial pathogens , 1995, Nature Genetics.

[31]  M. Braekeleer,et al.  Genotype-phenotype correlation in cystic fibrosis patients compound heterozygous for the A455E mutation , 1997, Human Genetics.

[32]  M. Corey,et al.  Detection of a cystic fibrosis modifier locus for meconium ileus on human chromosome 19q13 , 1999, Nature Genetics.

[33]  M. Goossens,et al.  Polyvariant mutant cystic fibrosis transmembrane conductance regulator genes. The polymorphic (Tg)m locus explains the partial penetrance of the T5 polymorphism as a disease mutation. , 1998, The Journal of clinical investigation.

[34]  C. Taylor,et al.  Liver disease in cystic fibrosis. , 1995, Archives of disease in childhood.

[35]  V. Raia,et al.  Detection of five rare cystic fibrosis mutations peculiar to Southern Italy: implications in screening for the disease and phenotype characterization for patients with homozygote mutations. , 1999, Clinical chemistry.

[36]  Cécile Fizames,et al.  A comprehensive genetic map of the human genome based on 5,264 microsatellites , 1996, Nature.

[37]  L. Silverman,et al.  Cystic fibrosis syndrome: a new paradigm for inherited disorders and implications for molecular diagnostics. , 1999, Clinical chemistry.

[38]  J. Price,et al.  Pulmonary dysfunction in cystic fibrosis is associated with oxidative stress. , 1996, The European respiratory journal.

[39]  E. Greenberg,et al.  Production of β-defensins by human airway epithelia , 1998 .

[40]  P. Pignatti,et al.  Pancreatic function and gene deletion F508 in cystic fibrosis. , 1990, Journal of medical genetics.

[41]  M. Corey,et al.  Genetic determination of exocrine pancreatic function in cystic fibrosis. , 1992, American journal of human genetics.

[42]  M Claustres,et al.  Mutations in the cystic fibrosis gene in patients with congenital absence of the vas deferens. , 1995, The New England journal of medicine.

[43]  J E Cotes,et al.  Lung volumes and forced ventilatory flows , 1993, European Respiratory Journal.

[44]  M. Schwartz,et al.  Association of mannose-binding lectin gene heterogeneity with severity of lung disease and survival in cystic fibrosis. , 1999, The Journal of clinical investigation.

[45]  L. Tsui,et al.  A cluster of cystic fibrosis mutations in the first nucleotide-binding fold of the cystic fibrosis conductance regulator protein , 1990, Nature.

[46]  J. Hull,et al.  Contribution of genetic factors other than CFTR to disease severity in cystic fibrosis , 1998, Thorax.

[47]  X. Estivill,et al.  Genetic differences in cystic fibrosis patients with and without pancreatic insufficiency , 1990, Human Genetics.

[48]  M. Ferrari,et al.  Analysis of risk factors for the development of liver disease associated with cystic fibrosis. , 1994, The Journal of pediatrics.

[49]  A. Hamosh,et al.  Severe deficiency of cystic fibrosis transmembrane conductance regulator messenger RNA carrying nonsense mutations R553X and W1316X in respiratory epithelial cells of patients with cystic fibrosis. , 1991, The Journal of clinical investigation.

[50]  B. Kerem,et al.  Association of a nonsense mutation (W1282X), the most common mutation in the Ashkenazi Jewish cystic fibrosis patients in Israel, with presentation of severe disease. , 1992, American journal of human genetics.

[51]  L. Tsui,et al.  Erratum: Identification of the Cystic Fibrosis Gene: Genetic Analysis , 1989, Science.

[52]  A. V. D. van den Ouweland,et al.  A cystic fibrosis mutation associated with mild lung disease. , 1995, The New England journal of medicine.

[53]  M. Devoto,et al.  Haplotypes in cystic fibrosis patients with or without pancreatic insufficiency from four European populations. , 1989, Genomics.

[54]  X. Estivill,et al.  Cystic fibrosis in Spain: high frequency of mutation G542X in the Mediterranean coastal area , 1993, Human Genetics.

[55]  E. Greenberg,et al.  Cystic Fibrosis Airway Epithelia Fail to Kill Bacteria Because of Abnormal Airway Surface Fluid , 1996, Cell.

[56]  M. Schwarz,et al.  TGF-β1 genotype and accelerated decline in lung function of patients with cystic fibrosis , 2000, Thorax.

[57]  Song-Lih Huang,et al.  Tumor Necrosis Factor- α Gene Polymorphism in Chronic Bronchitis , 1997 .

[58]  J C Olsen,et al.  A novel mutation in the cystic fibrosis gene in patients with pulmonary disease but normal sweat chloride concentrations. , 1994, The New England journal of medicine.

[59]  M. Griese,et al.  Surfactant protein A and other bronchoalveolar lavage fluid proteins are altered in cystic fibrosis. , 2001, The European respiratory journal.

[60]  M. Devoto,et al.  Four new mutations of the CFTR gene (541delC, R347H, R352Q, E585X) detected by DGGE analysis in Italian CF patients, associated with different clinical phenotypes , 1992, Human mutation.

[61]  P. Marynen,et al.  A child, homozygous for a stop codon in exon 11, shows milder cystic fibrosis symptoms than her heterozygous nephew , 1990, Journal of medical genetics.

[62]  D. Lomas,et al.  Secondary genetic factors in cystic fibrosis lung disease , 2000, Thorax.

[63]  L. Tsui,et al.  Two patients with cystic fibrosis, nonsense mutations in each cystic fibrosis gene, and mild pulmonary disease. , 1990, The New England journal of medicine.

[64]  J. Feingold,et al.  Association of variant alleles of mannose binding lectin with severity of pulmonary disease in cystic fibrosis: cohort study , 1999, BMJ.

[65]  M. Devoto,et al.  Cystic fibrosis patients with liver disease are not genetically distinct. , 1991, American journal of human genetics.

[66]  M. Leppert,et al.  Multiple mutations in highly conserved residues are found in mildly affected cystic fibrosis patients , 1990, Cell.

[67]  M. Ferrari,et al.  Search for mutations in pancreatic sufficient cystic fibrosis Italian patients: detection of 90% of molecular defects and identification of three novel mutations , 1995, Human Genetics.

[68]  A. Piazza,et al.  Genetic history of cystic fibrosis mutations in Italy. I. Regional distribution , 1997, Annals of human genetics.

[69]  T. Dörk,et al.  Detection of more than 50 different CFTR mutations in a large group of German cystic fibrosis patients , 1994, Human Genetics.

[70]  B. Wieringa,et al.  Dinucleotide repeat polymorphism at the D19S191 locus. , 1992, Nucleic acids research.

[71]  M. Knowles,et al.  Ion composition of airway surface liquid of patients with cystic fibrosis as compared with normal and disease-control subjects. , 1997, The Journal of clinical investigation.

[72]  B. Tümmler,et al.  Genetic determinants of airways' colonisation with Pseudomonas aeruginosa in cystic fibrosis , 1993, The Lancet.

[73]  X. Estivill,et al.  The genotype of a new linked DNA marker, MP6d-9, is related to the clinical course of cystic fibrosis. , 1990, Journal of medical genetics.

[74]  V. Raia,et al.  Clinical features of cystic fibrosis patients with rare genotypes. , 1996, Journal of medical genetics.

[75]  V. Raia,et al.  Liver expression in cystic fibrosis could be modulated by genetic factors different from the cystic fibrosis transmembrane regulator genotype. , 2001, American journal of medical genetics.

[76]  E. Girodon,et al.  Mild clinical phenotype associated with R1158X/S549R(T→G) CFTR genotype , 2000, Clinical genetics.

[77]  M. Hodson,et al.  Independent genetic determinants of pancreatic and pulmonary status in cystic fibrosis , 1990, The Lancet.